2018
DOI: 10.1016/j.ijpharm.2018.07.053
|View full text |Cite
|
Sign up to set email alerts
|

Intravaginal rings for continuous low-dose administration of cervical ripening agents

Abstract: Intravaginal rings (VRs) have been widely reported for administration of pharmaceutical drugs - most notably estrogens, progestogens and antiretrovirals - to the vagina for clinical benefit. Here, for the first time, we describe the design, manufacture and preclinical testing of VRs for sustained/controlled release of the cervical ripening agents isosorbide mononitrate (ISMN) and misoprostol (MP), either singly or in combination. Matrix-type silicone elastomer VRs containing ISMN showed declining daily release… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
2

Relationship

2
4

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 85 publications
0
6
0
Order By: Relevance
“…For example, adjusting the drug loading in a matrix-type ring will effectively modulate the release rate [17,55,64,66,156]. For reservoir-type rings, adjusting either the length of the internal drug-loaded reservoir or the thickness of the rate-controlling membrane will effectively modulate the release rate [17,36,64,128]. For pod-type rings, the drug release rate can be adjusted either by changing the number of pods included in the ring body or by modifying the design characteristics of the delivery channel [21,25].…”
Section: Different Levels Of Ivivcmentioning
confidence: 99%
See 1 more Smart Citation
“…For example, adjusting the drug loading in a matrix-type ring will effectively modulate the release rate [17,55,64,66,156]. For reservoir-type rings, adjusting either the length of the internal drug-loaded reservoir or the thickness of the rate-controlling membrane will effectively modulate the release rate [17,36,64,128]. For pod-type rings, the drug release rate can be adjusted either by changing the number of pods included in the ring body or by modifying the design characteristics of the delivery channel [21,25].…”
Section: Different Levels Of Ivivcmentioning
confidence: 99%
“…Interest in vaginal ring technology for drug delivery applications has piqued in recent years, driven primarily by a surge of innovation around the use of new ring designs and new polymeric materials for fabrication of rings. In fact, much of this innovation has stemmed directly from efforts to develop antiretroviral-releasing rings for prevention of HIV infection and multi-purpose prevention technologies the combine HIV prevention with contraception and prevention of other sexually transmitted infections [1][2][3]10,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]. In particular, great advances have been made in extending ring technology beyond conventional low molecular weight and relatively hydrophobic drugs to the formulation and release of hydrophilic drugs, biomolecular drugs and drug combinations.…”
Section: Introductionmentioning
confidence: 99%
“…Numerous other combination microbicide and multipurpose prevention technology (MPT) ringscapable of simultaneously releasing both a microbicide and a hormonal contraceptive agentare also in preclinical or early clinical development (Boyd et al, 2016;Ugaonkar et al, 2015), including a novel pod-type IVR capable of delivering the antiretroviral tenofovir disproxil fumarate alone or in combination with emtricitabine and maraviroc (Vincent et al, 2018). More recently, a vaginal ring designed to provide controlled release of the cervical ripening agents isosorbide mononitrate and misoprostol singly or in combination has been reported (Wang et al, 2018).…”
Section: Introductionmentioning
confidence: 99%
“…Experiments are performed with IVRs for human or preclinical use, or ring segments. An individual IVR or a ring segment is added to a specific volume of a (pre-heated) dissolution medium in a flask (entire ring), polypropylene tube [21], scintillation vial [34], glass bottle [35], or a sealed flask [36], and placed into an incubator shaker. The applied media volumes differ between experiments performed with ring segments, rings for preclinical use, and human IVRs.…”
Section: Current In Vitro Methods For Evaluating Drug Release Of Imentioning
confidence: 99%
“…Consequently, the volumes of test media used for in vitro drug release experiments with macaque-sized IVRs are often significantly smaller than those used in human IVR experiments [24,37,38,39,40]. The reported agitation speeds in shake-flask experiments range from 60 rpm [31,35,36,37,38,39,40,41,42,43,44,45,46,47,48,70,75,78,79,80] through 80 rpm [51,52,53,54,73], 100 rpm [10,56,57,58,71] and 110 rpm [17] to 130 rpm [34,49,50,81,82].…”
Section: Current In Vitro Methods For Evaluating Drug Release Of Imentioning
confidence: 99%